EU extends Pfizer, Hospira review to assess remedies
The European Commission has extended its review of Pfizer’s buyout of injectable-drugs maker Hospira to assess commitments the drug giant has proposed to ease concerns about the $17 billion deal. The...To view the full article, register now.
Already a subscriber? Click here to view full article